HKSE - Delayed Quote HKD

Pharmaron Beijing Co., Ltd. (3759.HK)

Compare
13.000 -0.300 (-2.26%)
At close: January 3 at 4:08:07 PM GMT+8
Loading Chart for 3759.HK
DELL
  • Previous Close 13.300
  • Open 13.420
  • Bid 13.000 x --
  • Ask 13.020 x --
  • Day's Range 13.000 - 13.580
  • 52 Week Range 7.980 - 24.850
  • Volume 3,989,908
  • Avg. Volume 11,341,843
  • Market Cap (intraday) 42.259B
  • Beta (5Y Monthly) 0.83
  • PE Ratio (TTM) 11.50
  • EPS (TTM) 1.130
  • Earnings Date Mar 25, 2025 - Mar 31, 2025
  • Forward Dividend & Yield 0.22 (1.69%)
  • Ex-Dividend Date Jun 27, 2024
  • 1y Target Est 18.00

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vitro biology, DMPK, in vivo pharmacology, and compound management services; chemistry, manufacturing, and controls services. It also provides clinical development services, including integrated radio labelled science, clinical development, and clinical trial recruitment services; safety assessment, integrated drug discovery, and bioanalysis services; and biologics and cell and gene therapy services, comprising biologics laboratory, biologics CDMO, cell and gene therapy laboratory, and gene therapy CDMO services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

www.pharmaron.com

20,295

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 3759.HK

View More

Performance Overview: 3759.HK

Trailing total returns as of 1/3/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

3759.HK
7.80%
SSE Composite Index
5.75%

1-Year Return

3759.HK
13.53%
SSE Composite Index
8.41%

3-Year Return

3759.HK
74.40%
SSE Composite Index
11.77%

5-Year Return

3759.HK
27.13%
SSE Composite Index
4.09%

Compare To: 3759.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 3759.HK

View More

Valuation Measures

As of 1/3/2025
  • Market Cap

    42.23B

  • Enterprise Value

    45.68B

  • Trailing P/E

    11.50

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.84

  • Price/Book (mrq)

    1.62

  • Enterprise Value/Revenue

    3.64

  • Enterprise Value/EBITDA

    18.03

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.97%

  • Return on Assets (ttm)

    4.15%

  • Return on Equity (ttm)

    13.58%

  • Revenue (ttm)

    11.8B

  • Net Income Avi to Common (ttm)

    1.88B

  • Diluted EPS (ttm)

    1.130

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.6B

  • Total Debt/Equity (mrq)

    41.63%

  • Levered Free Cash Flow (ttm)

    -221.68M

Research Analysis: 3759.HK

View More

People Also Watch